The primary objective is to determine the nature and degree of the toxicity of weekly dosing
of topotecan in escalating dose levels by cohorts of 3-6 patients in combination with a fixed
dose of pegylated liposomal doxorubicin (Doxil).
The secondary objective is to determine the activity of weekly topotecan and pegylated
liposomal doxorubicin in advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Christiana Care Health Services
Collaborators:
GlaxoSmithKline Johnson & Johnson
Treatments:
Doxorubicin Liposomal doxorubicin Topoisomerase I Inhibitors Topotecan